ArticleFrontiers in behavioral neuroscience2026
Unbiased autoantibody screening using nucleic acid protein programmable array in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections.
Article in Frontiers in behavioral neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) is characterized by the abrupt onset of obsessive-compulsive disorder and/or tics, along with other neuropsychiatric symptoms in children, in the setting of Group A beta-hemolytic streptococcus infection and presumed immune dysregulation. Current diagnostic testing has limited utility in diagnosis of PANDAS. Methods: The Nucleic Acid Protein Programmable Array (NAPPA) is a protein expression system that enables the study of protein-autoantibody interactions. We employed this system for unbiased screening of potential autoimmune targets in PANDAS. Results: Initially, we compared children with PANDAS to patients with autism spectrum disorder (ASD) and identified 1,235 non-overlapping protein targets. These targets were subsequently used to re-screen samples from PANDAS, ASD and healthy controls (HC). In the secondary screen, 117 autoantibody targets were exclusively detected in PANDAS and absent from both ASD and HC groups. However, autoantibody profiles were highly heterogeneous: 67.5% of PANDAS-positive targets were reactive in only a single patient, and no individual protein or multi-protein panel classifier achieved reliable diagnostic discrimination under proper cross-validation. Targets that discriminated PANDAS from HC largely failed to discriminate PANDAS from ASD, and vice versa, indicating that autoantibody-based diagnosis is confounded by reactivity shared across neuropsychiatric conditions. Despite poor diagnostic performance, functional enrichment analysis revealed that PANDAS-specific targets were significantly overrepresented among transcription factors, apoptosis regulators, chromatin/epigenetic modifiers, neural development proteins, and immune-regulatory molecules, with the majority being intracellular proteins enriched for intrinsically disordered regions. Discussion: These findings support the hypothesis of autoimmunity and epitope spreading as features of PANDAS but indicate that the heterogeneity of the humoral response represents a fundamental challenge for serological diagnosis. Future studies with larger cohorts and complementary approaches are necessary to determine whether autoantibody signatures can be leveraged for clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.